Mesothelioma Doctors / Physicians
Daniel Sterman, M.D.
- Title
- Assistant Professor of Medicine, University of Pennsylvania Medical Center, Philadelphia, PA
- Phone
- (215) 614-0984
- Education
-
- A.B., European History, Brown University, 1985
- M.D., Cornell University Medical College, 1989
- Residency
- Internal Medicine, Hospital of the University of Pennsylvania
- Fellowship
- Pulmonary and Critical Care Medicine, Hospital of the University of Pennsylvania
- Board Certifications
-
- Internal Medicine
- Pulmonary Medicine
- Critical Care Medicine
- Clinical Expertise
- Thoracic Oncology, specifically lung cancer, malignant mesothelioma and mediastinal tumors
- Website
- Biography/CV
(will open new window)
Dr. Sterman received his A.B. in European History from Brown University in
1985, and his M.D. from Cornell University Medical College in 1989. He then
pursued his Internship and Residency in Internal Medicine at the Hospital of the
University of Pennsylvania from 1989-1992; followed by an Instructorship in
Emergency Medicine also at HUP from 1992-93. Subsequently, Dr. Sterman received
fellowship training in Pulmonary and Critical Care Medicine at the University of
Pennsylvania Medical Center from 1993-1997. While a fellow, he received advanced
training in Interventional Bronchoscopy and Pleuroscopy with Dr. Michael Unger
at Pennsylvania Hospital, and with Dr. Larry Kaiser of the HUP Division of
General Thoracic Surgery. In addition, he was a Postdoctoral Research Fellow in
the Thoracic Oncology Research Laboratory of the University of Pennsylvania
Medical Center under the tutelage of Dr. Steven Albelda. After spending two
years in the Thoracic Oncology Laboratories working with Drs. Albelda and
Kaiser, he joined the faculty at PENN in 1997 as an Assistant Professor of
Medicine in the Pulmonary Division and was the recipient of a NIH Clinical
Associate Physician Award. Dr. Sterman is board certified in Internal Medicine,
Pulmonary Medicine, and Critical Care Medicine.
Dr. Sterman is currently Associate Professor of Medicine and Associate Professor
of Medicine in Surgery, and the Director of the PENN Interventional Pulmonology
Program and Clinical Director of the Thoracic Oncology Gene Therapy Program of
the Center for Lung Cancer and Related Disorders of the University of
Pennsylvania Medical Center. Dr. Sterman has advanced training in the following
techniques: flexible and rigid bronchoscopy; balloon bronchoplasty,
endobronchial stent placement (metal, hybrid, and silicone), endobronchial
brachytherapy, photodynamic therapy, auto-fluorescence bronchoscopy (LIFE),
transbronchial needle aspiration/biopsy, bronchoscopic electrosurgery (including
APC), endobronchial ultrasound (radial and convex probe), percutaneous
tracheotomy, and pleuroscopy. His clinical interests are related to the
treatment of thoracic malignancies, specifically as they apply to the synergy of
molecular medicine and novel technologies in Interventional Pulmonology. His
research interests are in the translation of laboratory discoveries from the
bench to the bedside: conducting human clinical trials of gene therapy and
vaccine therapy for lung cancer, mesothelioma, and other pleural malignancies.
Dr. Sterman is the lead clinical investigators in the multidisciplinary Thoracic
Oncology Research Group at Penn and has been the Principal Investigator of
Project 1 (Clinical Trials Project) for this NCI Program Project Grant since
1998. He is currently the sponsor and Principal Investigator of the ongoing
Ad.IFN-beta gene therapy trial aimed at cancer patients with mesothelioma and
metastatic pleural disease. In addition, he has led a number of other
industry-sponsored cancer clinical trials, all with extramural funding. He
served as the Principal Investigator at Penn of a series of Multicenter Phase II
Clinical Trials, sponsored by Cell Genesys, Inc, evaluating patient-specific
lung cancer vaccines. He is currently participating in a multicenter,
randomized, double-blinded Phase III clinical trial of a recombinant MUC-1
vaccine for Stage III NSCLC patients with stable/responding disease status post
definitive chemoradiotherapy.
More recently, in collaboration with other members of the clinical trials group
from the Thoracic Oncology Research Laboratory, composed of members from
Pulmonary Medicine, Medical Oncology, and Thoracic Surgery, Dr. Sterman is
conducting a series of trials focused on the concept of genetic immunotherapy
for thoracic malignancies (bronchogenic, carcinoma, mesothelioma, metastatic
pleural disease). The hallmark of this program is our ongoing Phase I clinical
trial of intrapleural adenovirus mediated human interferon gene transfer for
patients with pleural malignancies. Dr. Sterman and colleagues are developing
trial involving delivery of the interferon-alpha gene via adenoviral vector,
with the goal of combining this experimental treatment with standard combination
chemotherapy, based upon success in pre-clinical studies.
In addition, Dr. Sterman and colleagues will be initiating a multicenter
Phase I trial of intravenous delivery of a recombinant, attenuated Listeria
monocytogenes bacterial vector expressing the gene for human Mesothelin, a cell
surface protein expressed on 50% of non-small cell lung cancers and nearly 100%
of mesotheliomas. He is also developing, with Dr. Steven Albelda, a clinical
trial of bronchoscopic injection of a recombinant, replication competent
Vaccinia viral vector expressing the human GM-CSF gene with patients with
refractory small cell and non-small cell carcinoma of the lung, which will be
enrolling patients in 2008.
Dr. Sterman has also been involved in pioneering clinical research projects
aimed at developing advanced bronchoscopic techniques to treat diseases such as
tracheomalacia, severe asthma, and emphysema.
|
|